Entering text into the input field will update the search result below

Inovio Pharmaceuticals results miss on the bottom line; shares down 9%

Mar. 01, 2022 4:42 PM ETInovio Pharmaceuticals, Inc. (INO)By: Jonathan Block, SA News Editor11 Comments

Quarterly results

CharlieAJA/iStock via Getty Images

  • Inovio Pharmaceuticals' (NASDAQ:INO) Q4 2021 results missed on the bottom line as its net loss significantly widened.
  • Shares are down 9% in after-market trading.
  • Net loss in the quarter was $106.9M, ~340% increase from the prior-year period. Basic and diluted EPS

Recommended For You

Comments (11)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Inovio’s research and development expenses for the quarter and year ended December 31, 2021 were $92.3 million and $249.2 million, compared to $26.3 million and $94.2 million for the same periods in 2020.

So they are burning thru cash at x3 times the rate of last year to hopefully produce a vaccine. Seems like they would be better off stopping all Covid actions and preserve capital for the next pandemic.
@Randol33 absolutely
Covid vaccine is just a waste of money!! They should stop ASAP.
I guess the world will have to wait.
@Fender5 for what?
@break-point exactly. It’s on the front page of Inovio’s website.
@Fender5 I have seen now....
Buried in the press release: they paused enrollments in their Covid P3 trial.
stephen tips profile picture
"Seeking Alpha Contributor William Meyers considers Inovio (INO) a buy."

I believe that Mr. Meyers is spot on with his recommendation. He, as I, agree that VGX-3100 (now in the later stages of P3), should be the first FDA-approved commercial product for Inovio.

Inovio's covid-19 vaccine, INO-4800, could be a bonus for $INO, all recipients, shareholders and directors alike.

Quarterly earnings reports are not an indicator of future potential for clinical stage biotechnology companies that lack any commercial product. The year end $401.3M in cash is much more telling.
I remember trading weekly calls, this time last year.
Easy money.

Then parked the money elsewhere.

HPV vaccine work is the only reason to keep this stock and can save it.
LOL. try down -75% from $31.25 it just happens to be down -10% after hours.

About INO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Inovio Pharmaceuticals, Inc.
Cue Biopharma, Inc.
Cyteir Therapeutics, Inc.
Vaxxinity, Inc.
BioLineRx Ltd.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.